Views & Analysis Collaboration can ensure access to life-changing innovation As a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new care infrastructure.
Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
News Sobi plans filings for gout drug after phase 3 readout SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
